Search results

560 results

Sorted by Date . Sort by Relevance

In development Remove In development filter
Technology appraisal guidance Remove Technology appraisal guidance filter
Clinical guidelines Remove Clinical guidelines filter
Diagnostics guidance Remove Diagnostics guidance filter
Highly specialised technologies guidance Remove Highly specialised technologies guidance filter
Safe staffing guidelines Remove Safe staffing guidelines filter
Social care guidelines Remove Social care guidelines filter
Medicines practice guidelines Remove Medicines practice guidelines filter

Elotuzumab with pomalidomide and dexamethasone for treating multiple myeloma after 2 therapies ID1467

In development [GID-TA10353] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Constipation (opioid induced) - methylnaltrexone bromide [ID700]

In development [GID-TA10003] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Leukaemia (chronic lymphocytic) - idelalisib (with ofatumumab) [ID817]

In development [GID-TA10008] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Reducing the mortality and morbidity for healthcare associated infections

In development [GID-NG10059] Expected publication date: TBC

Type

NICE guideline

Status

In development
Dapagliflozin, empagliflozin and sotagliflozin for treating type 1 diabetes [ID1217]

In development [GID-TA10236] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Breast cancer (HER2 negative, HR positive) - everolimus (with exemestane, after endocrine therapy) [ID965]

In development [GID-TA10028] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Hernia

In development [GID-CGWAVE0771] Expected publication date: TBC

Type

NICE guideline

Status

In development
Ofatumumab (Arzerra) in combination with chemotherapy for follicular lymphoma; second line - refractory to rituximab ID1487

In development [GID-TA10437] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Ibrutinib combination therapy for untreated diffuse large B-cell lymphoma ID997

In development [GID-TA10382] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Atezolizumab plus bevacizumab for untreated locally advanced or metastatic renal cell carcinoma [ID1365]

In development [GID-TA10338] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Nivolumab for previously treated gastric or gastro-oesophageal junction cancer [ID1118]

In development [GID-TA10151] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Daratumumab in combination for untreated multiple myeloma when stem cell transplant is unsuitable ID1492

In development [GID-TA10441] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Betrixaban for preventing venous thromboembolism in people hospitalised for acute medical conditions [ID913]

In development [GID-TA10154] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Renal cell carcinoma - sunitinib [ID1076]

In development [GID-TA10166] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Osteoarthritis - diacerein [ID332]

In development [GID-TAG250] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Durvalumab for treating metastatic urothelial bladder cancer after chemotherapy ID1172

In development [GID-TA10394] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Cositecan for treating platinum or taxane resistant advanced, mucinous, epithelial ovarian cancer [ID826]

In development [GID-TA10446] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Avelumab for previously treated platinum-resistant ovarian cancer ID1497

In development [GID-TA10404] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
ATIR101 with haploidentical haematopoietic stem cell transplantation for haematological cancers [ID1093]

In development [GID-TA10445] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Canakinumab for preventing cardiovascular events after myocardial infarction in people with raised high-sensitivity C-reactive protein (ID1362)

In development [GID-TA10337] Expected publication date: 19 February 2020

Type

Technology appraisal guidance

Status

In development
Pacritinib for treating myelofibrosis [ID880]

In development [GID-TA10133] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
LJ TEST

In development [GID-TA10462] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Rovalpituzumab tesirine for treating small-cell lung cancer after 2 therapies ID1288

In development [GID-TA10212] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Pembrolizumab for untreated PD-L1 positive non-small-cell lung cancer with at least 1% tumour proportion score [ID1247]

In development [GID-TA10271] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Histamine dihydrochloride with interleukin-2 for maintenance treatment of acute myeloid leukaemia [ID1627]

In development [GID-TA10575] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Safe prescribing and withdrawal management of prescribed drugs associated with dependence and withdrawal

In development [GID-NG10141] Expected publication date: 17 November 2021

Type

NICE guideline

Status

In development
Atezolizumab with cobimetinib and vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma [ID1674]

In development [GID-TA10543] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma ID1352

In development [GID-TA10319] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Luspatercept for treating anaemia caused by myelodysplastic syndromes [ID1550]

In development [GID-TA10508] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Atezolizumab for adjuvant treatment of resected high-risk muscle-invasive urothelial cancer [ID2730]

In development [GID-TA10623] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Nivolumab with ipilimumab for untreated PD-L1 mutation-positive non-small-cell lung cancer [ID1675]

In development [GID-TA10585] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Nivolumab in combination for treating hormone-relapsed metastatic prostate cancer before chemotherapy [ID1619]

In development [GID-TA10490] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Nivolumab in combination for treating hormone-relapsed metastatic prostate cancer after chemotherapy [ID1621]

In development [GID-TA10492] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Nivolumab for treating platinum-resistant advanced or recurrent ovarian cancer [ID2714]

In development [GID-TA10590] Expected publication date: 19 May 2021

Type

Technology appraisal guidance

Status

In development
Liraglutide for managing obesity in people aged 12 to 17 [ID1630]

In development [GID-TA10563] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Carfilzomib with daratumumab and dexamethasone for treating relapsed or refractory multiple myeloma [ID2709]

In development [GID-TA10579] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
KTE-X19 for previously treated B-precursor acute lymphoblastic leukaemia ID1494

In development [GID-TA10424] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Ramucirumab with erlotinib for untreated EGFR-positive metastatic non-small-cell lung cancer [ID1665]

In development [GID-TA10550] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 1 systemic therapy [ID1684]

In development [GID-TA10580] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Axicabtagene ciloleucel for treating relapsed or refractory low-grade non-Hodgkin lymphoma [ID1685]

In development [GID-TA10578] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Ropeginterferon alfa-2b for treating polycythaemia vera without symptomatic splenomegaly ID1596

In development [GID-TA10497] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Nivolumab with ipilimumab for neoadjuvant treatment of early non-small-cell lung cancer [ID3756]

In development [GID-TA10631] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Listeria monocytogenes vaccine for previously treated malignant pleural mesothelioma ID1353

In development [GID-TA10320] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Tisotumab vedotin for treating recurrent or metastatic cervical cancer after systemic therapy [ID3753]

In development [GID-TA10620] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
ERC1671 for treating progressed or recurrent grade IV glioma (glioblastoma or gliosarcoma) [ID1623]

In development [GID-TA10489] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Apalutamide for treating non-metastatic, hormone-relapsed prostate cancer [ID1174]

In development [GID-TA10377] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
ADI-PEG 20 for previously treated hepatocellular carcinoma [ID1025]

In development [GID-TA10259] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Abemaciclib for treating KRAS mutation-positive non-small-cell lung cancer after platinum-based chemotherapy ID1147

In development [GID-TA10343] Expected publication date: TBC

Type

Technology appraisal guidance

Status

In development
Lysosomal acid lipase deficiency - sebelipase alfa [ID737]

In development [GID-LYSOSOMALACIDLIPASEDEFICIENCYSEBELIPASEALFAID737] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

In development
Afamelanotide for treating erythropoietic protoporphyria [ID927]

In development [GID-HST10009] Expected publication date: TBC

Type

Highly specialised technologies guidance

Status

In development